AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30586261 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion
Number of subjects: 212
Study 30586261 — intervention group
Group type: COMPARATOR
Intervention: TAZ
Number of subjects: 212
Study 30586261 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 212
Study 30586261 — intervention group
Group type: COMPARATOR
Intervention: HP
Number of subjects: 212
Study 27780256 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (APP) based on Android system to read 2D chemical barcodes
Number of subjects: 3
Study 27780256 — intervention group
Group type: EXPERIMENTAL
Intervention: QR codes as an effective information carrier
Number of subjects: 3
Study 27780256 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear interpolation angle cosine similarity algorithm (LIACSA)
Number of subjects: 3
Study 24082027 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based podcast intervention
Number of subjects: 66
Study 24082027 — intervention group
Group type: COMPARATOR
Intervention: Control podcast
Number of subjects: 66
Study 22353433 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (MyHealth Online, a patient portal with interactive health applications)
Number of subjects: 201
Study 22353433 — intervention group
Group type: COMPARATOR
Intervention: Control group (health education website with various topics)
Number of subjects: 201
Study 20823433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus folinic acid (20 mg/m² intravenous bolus injection followed by 425 mg/m² intravenous bolus injection given 1-5 days every 28 days)
Number of subjects: 1088
Study 20823433 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m² intravenous infusion once a week for 3 of every 4 weeks)
Number of subjects: 1088
Study 18166759 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine ampules labeled with mass concentration (1 mg in 1 mL)
Number of subjects: 28
Study 18166759 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine ampules labeled with ratio (1 mL of a 1:1000 solution)
Number of subjects: 28
Study 16170757 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual support measures and scripted serial telephone calls (16 calls during 96 weeks)
Number of subjects: 282
Study 16170757 — intervention group
Group type: COMPARATOR
Intervention: Usual support measures
Number of subjects: 282
Study 12753315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 273
Study 12753315 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 273
Study 12753315 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 273
Study 11154807 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-day praziquantel therapy (n=14)
Number of subjects: 26
Study 11154807 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (n=12)
Number of subjects: 26
Study 11154807 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment after non-treatment
Number of subjects: 26
Study 11154807 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive patients (n=14)
Number of subjects: 26
Study 11154807 — intervention group
Group type: EXPERIMENTAL
Intervention: Seronegative patients (n=12)
Number of subjects: 26
Study 9055539 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE (Extracapsular Cataract Extraction)
Number of subjects: 39
Study 9055539 — intervention group
Group type: EXPERIMENTAL
Intervention: PEA (Phacoemulsification and Aspiration)
Number of subjects: 39
Study 1829091 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of long and short acting GnRH analogues (group II)
Number of subjects: 34
Study 1829091 — intervention group
Group type: COMPARATOR
Intervention: Induction of ovulation with decapeptyl/PFSH/HMG/HCG (group I)
Number of subjects: 34
Study 6673029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1,200 mg/day for 30 days)
Number of subjects: 20
Study 6673029 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 20
Study 31907774 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Physical Activity Program (HB-PAP)
Number of subjects: 17
Study 31907774 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study 31237645 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy after 3 months of DAPT (n=1495)
Number of subjects: 2993
Study 31237645 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) for 12 months (n=1498)
Number of subjects: 2993
Study 31237645 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy
Number of subjects: 2993
Study 31237645 — intervention group
Group type: COMPARATOR
Intervention: DAPT
Number of subjects: 2993
Study 27667369 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIGATE treatment (comprehensive, team-based treatment program with ≥5h of SEE services per week)
Number of subjects: 404
Study 27768193 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational intervention consisting of interactive video tutorials (RLOs) delivered through DVD for TV or PC, and online.
Number of subjects: 0
Study 27768193 — intervention group
Group type: EXPERIMENTAL
Intervention: RLOs watched fewer times by users with higher Internet competency.
Number of subjects: 0
Study 25097397 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of beta urogastrone (recombinant human epidermal growth factor) gel
Number of subjects: 50
Study 25097397 — intervention group
Group type: COMPARATOR
Intervention: Betadine dressing (Control)
Number of subjects: 50
Study 23210239 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide tablets from Yuanlijian (test)
Number of subjects: 20
Study 23210239 — intervention group
Group type: COMPARATOR
Intervention: Rebamipide tablets from Otsuka (reference)
Number of subjects: 20
Study 20703499 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail running competition
Number of subjects: 23
Study 18563785 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood test (FOBT) screening, rehydrated Hemoccult‐II, screened two to three times, compliance 70.0% (23,916 individuals)
Number of subjects: 68308
Study 18563785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 68308
Study 15868146 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly for up to 840 days)
Number of subjects: 476
Study 11840227 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin re-uptake inhibitor (SSRI) treatment
Number of subjects: 11
Study 11840227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10599031 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIIa
Number of subjects: 16
Study 10599031 — intervention group
Group type: EXPERIMENTAL
Intervention: von Willebrand factor (vWF)
Number of subjects: 16
Study 10599031 — intervention group
Group type: COMPARATOR
Intervention: Group II (NIDDM)
Number of subjects: 16
Study 8443642 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ grafts
Number of subjects: 162
Study 8443642 — intervention group
Group type: COMPARATOR
Intervention: Reversed vein grafts
Number of subjects: 162
Study 8443642 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ grafts (small veins subgroup)
Number of subjects: 162
Study 8443642 — intervention group
Group type: COMPARATOR
Intervention: Reversed vein grafts (small veins subgroup)
Number of subjects: 162
Study 3094350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (200 micrograms)
Number of subjects: 52
Study 3094350 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive hyperemia
Number of subjects: 52
Study 3094350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolazoline
Number of subjects: 52
Study 3094350 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 52
Study 30272528 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 μg/day iodine
Number of subjects: 240
Study 30272528 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg/day iodine
Number of subjects: 240
Study 30272528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 30272528 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed group
Number of subjects: 240
Study 26761728 — intervention group
Group type: EXPERIMENTAL
Intervention: HRRP policy exposure (hospitals facing greater financial risk)
Number of subjects: 0
Study 25733331 — intervention group
Group type: EXPERIMENTAL
Intervention: Large doses of ambroxol hydrochloride
Number of subjects: 56
Study 25733331 — intervention group
Group type: COMPARATOR
Intervention: Normal doses of ambroxol hydrochloride
Number of subjects: 56
Study 23941563 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy of the Participatory Approach (PA) including a working group, supervisor training, and supervisor coaching.
Number of subjects: 0
Study 23941563 — intervention group
Group type: COMPARATOR
Intervention: Minimal implementation strategy of the Participatory Approach (PA) consisting of written information only.
Number of subjects: 0
Study 23941563 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy of the Participatory Approach (PA)
Number of subjects: 0
Study 23941563 — intervention group
Group type: COMPARATOR
Intervention: Minimal implementation strategy of the Participatory Approach (PA)
Number of subjects: 0
Study 21194660 — intervention group
Group type: EXPERIMENTAL
Intervention: No cost group (hard shell hip protectors without cost)
Number of subjects: 234
Study 21194660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (educational session, demonstration, and free choice of hip protectors without cost)
Number of subjects: 234
Study 21194660 — intervention group
Group type: COMPARATOR
Intervention: Control group (brochure about hip protectors)
Number of subjects: 234
Study 21194660 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 234
Study 19235751 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact endoscopy in the non-RT group
Number of subjects: 157
Study 19235751 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact endoscopy in the post-RT group
Number of subjects: 157
Study 17032185 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone titrated to deep sedation
Number of subjects: 200
Study 17032185 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (fentanyl plus propofol, midazolam plus propofol, fentanyl plus midazolam plus propofol)
Number of subjects: 200
Study 17032185 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and propofol
Number of subjects: 200
Study 12750084 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 50
Study 12750084 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 50
Study 10669283 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine 6.0 mg/kg
Number of subjects: 100
Study 10669283 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam 0.5 mg/kg and diclofenac 12.5 mg
Number of subjects: 100
Study 10669283 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 5 microg/kg
Number of subjects: 100
Study 10669283 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 100
Study 10669283 — intervention group
Group type: EXPERIMENTAL
Intervention: Group KS (ketamine)
Number of subjects: 100
Study 10669283 — intervention group
Group type: COMPARATOR
Intervention: Group DS (diazepam/diclofenac)
Number of subjects: 100
Study 10669283 — intervention group
Group type: EXPERIMENTAL
Intervention: Group KG (ketamine with glycopyrrolate)
Number of subjects: 100
Study 9602199 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 32
Study 9602199 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 32
Study 7845777 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 33
Study 7845777 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 33
Study 7845777 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 33
Study 3177831 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg) combined with Piritramid (0.1 mg/kg)
Number of subjects: 70
Study 3177831 — intervention group
Group type: COMPARATOR
Intervention: Thalamonal (0.04 ml/kg)
Number of subjects: 70
Study 30676232 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body resistance exercise program for 8 weeks, 3 sessions per week.
Number of subjects: 34
Study 30676232 — intervention group
Group type: COMPARATOR
Intervention: Usual care and daily activities (Control group).
Number of subjects: 34
Study 30897129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education and diet plan
Number of subjects: 115
Study 30897129 — intervention group
Group type: COMPARATOR
Intervention: General education only (Control)
Number of subjects: 115
Study 29031658 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.33% topical gel
Number of subjects: 24
Study 29031658 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care MMS
Number of subjects: 24
Study 26337307 — intervention group
Group type: EXPERIMENTAL
Intervention: DIABENIL* (generic product)
Number of subjects: 24
Study 26337307 — intervention group
Group type: COMPARATOR
Intervention: DAONIL* (reference product)
Number of subjects: 24
Study 23804960 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal intervention in Year 2
Number of subjects: 120
Study 23804960 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention in Year 2)
Number of subjects: 120
Study 21166575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy targeting normal glycosylated hemoglobin (HbA1c) levels, tight lipid control with fenofibrate and statin, aggressive blood pressure treatment with a systolic blood pressure goal of 120 mmHg
Number of subjects: 10251
Study 21166575 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 10251
Study 18326590 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT-MCT
Number of subjects: 12
Study 18326590 — intervention group
Group type: COMPARATOR
Intervention: LCT
Number of subjects: 12
Study 18326590 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 16579491 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear, slow‐acting AVC hearing aids
Number of subjects: 50
Study 16579491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast‐acting WDRC hearing aids
Number of subjects: 50
Study 16579491 — intervention group
Group type: EXPERIMENTAL
Intervention: WDRC in two channels
Number of subjects: 50
Study 16579491 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid with WDRC in low-frequency and AVC in high-frequency channel
Number of subjects: 50
Study 16579491 — intervention group
Group type: EXPERIMENTAL
Intervention: All nonlinear fittings
Number of subjects: 50
Study 14608527 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12
Study 14608527 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 12
Study 14608527 — intervention group
Group type: COMPARATOR
Intervention: Control (Normotensive volunteers)
Number of subjects: 12
Study 10950060 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion strategy (immediate conversion from sigmoidoscopy to colonoscopy)
Number of subjects: 235
Study 10950060 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional sigmoidoscopy followed by colonoscopy on a future day)
Number of subjects: 235
Study 10950060 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 235
Study 10950060 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-reported outcomes
Number of subjects: 235
Study 8737633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 400 mg of buflomedil during 4 h of dialysis
Number of subjects: 10
Study 8737633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of buflomedil in six other patients maintained on intermittent hemodialysis (3 per week) for 4 weeks
Number of subjects: 10
Study 1350365 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 12
Study 1350365 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms)
Number of subjects: 12
Study 1350365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4032130 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (supervised exercise program, 3 times a week, walking or running 3 miles)
Number of subjects: 0
Study 4032130 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 0
Study 31851170 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% articaine solution
Number of subjects: 43
Study 31851170 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine solution
Number of subjects: 43
Study 30152537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management intervention
Number of subjects: 70
Study 27581655 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI smartphone application (EPI app) and reminder text messages
Number of subjects: 32
Study 27581655 — intervention group
Group type: COMPARATOR
Intervention: Usual procedures and text messages
Number of subjects: 32
Study 27581655 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI smartphone application (EPI app)
Number of subjects: 32
Study 24525598 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin-based dialysis solution (ICO group)
Number of subjects: 59
Study 24525598 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based dialysis fluid (GLU group)
Number of subjects: 59
Study 22889955 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX) (60 mg/day) plus SOC (PegIFNα2a 180 μg/week and RBV 600‐1,000 mg/day)
Number of subjects: 123
Study 22889955 — intervention group
Group type: COMPARATOR
Intervention: SOC only (PegIFNα2a 180 μg/week and RBV 600‐1,000 mg/day)
Number of subjects: 123
Study 22889955 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX) plus SOC in patients with IL28B TT
Number of subjects: 123
Study 22889955 — intervention group
Group type: COMPARATOR
Intervention: SOC only in patients with IL28B TT
Number of subjects: 123
Study 20233275 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil ODT on demand
Number of subjects: 409
Study 20233275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 18060266 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 50
Study 18060266 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 50
Study 18060266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion-releasing composite
Number of subjects: 50
Study 18060266 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured composite resin (Z-100)
Number of subjects: 50
Study 18060266 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured, fluoride-containing composite resin (Heliomolar)
Number of subjects: 50
Study 16100448 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (fluticasone propionate 1,000 microgram/day) for 4 weeks
Number of subjects: 60
Study 12708095 — intervention group
Group type: EXPERIMENTAL
Intervention: Short monophasic form
Number of subjects: 29
Study 12708095 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic form
Number of subjects: 29
Study 12708095 — intervention group
Group type: EXPERIMENTAL
Intervention: Long monophasic form
Number of subjects: 29
Study 10084469 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol powder (50 microg) twice daily for 52 weeks
Number of subjects: 352
Study 10084469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 7736395 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to screening for women aged 40-74 years
Number of subjects: 133065
Study 7736395 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to screening for women aged 50-74 years
Number of subjects: 133065
Study 7736395 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to screening for women aged 40-49 years
Number of subjects: 133065
Study 7736395 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening regime for women aged 40-49 years
Number of subjects: 133065
Study 2202792 — intervention group
Group type: COMPARATOR
Intervention: 10 U/mL heparin (H)
Number of subjects: 45
Study 2202792 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 U/mL heparin and 25 micrograms/mL vancomycin (H-V)
Number of subjects: 45
Study 375172 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 146
Study 375172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 31201957 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil (KO) supplementation (5 g)
Number of subjects: 10
Study 31201957 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (FO) supplementation (5 g)
Number of subjects: 10
Study 28431420 — intervention group
Group type: EXPERIMENTAL
Intervention: Generative Retrieval (GR)
Number of subjects: 30
Study 28431420 — intervention group
Group type: COMPARATOR
Intervention: Standard Practice (SP)
Number of subjects: 30
Study 25869324 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ibuprofen (HDI)
Number of subjects: 72
Study 23987561 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing)
Number of subjects: 40
Study 23987561 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 40
Study 23987561 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 40
Study 21825007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocodazole
Number of subjects: 0
Study 21825007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocodazole combined with dexamethasone
Number of subjects: 0
Study 19214599 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep extensor muscle‐preserving laminoplasty (MP group)
Number of subjects: 84
Study 19214599 — intervention group
Group type: COMPARATOR
Intervention: Conventional open‐door laminoplasty (CL group)
Number of subjects: 84